346 related articles for article (PubMed ID: 11320250)
1. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
Ruffner H; Joazeiro CA; Hemmati D; Hunter T; Verma IM
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5134-9. PubMed ID: 11320250
[TBL] [Abstract][Full Text] [Related]
2. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Brzovic PS; Keeffe JR; Nishikawa H; Miyamoto K; Fox D; Fukuda M; Ohta T; Klevit R
Proc Natl Acad Sci U S A; 2003 May; 100(10):5646-51. PubMed ID: 12732733
[TBL] [Abstract][Full Text] [Related]
3. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Brzovic PS; Rajagopal P; Hoyt DW; King MC; Klevit RE
Nat Struct Biol; 2001 Oct; 8(10):833-7. PubMed ID: 11573085
[TBL] [Abstract][Full Text] [Related]
4. The BRCA1/BARD1 ubiquitin ligase and its substrates.
Witus SR; Stewart MD; Klevit RE
Biochem J; 2021 Sep; 478(18):3467-3483. PubMed ID: 34591954
[TBL] [Abstract][Full Text] [Related]
5. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.
Baer R; Ludwig T
Curr Opin Genet Dev; 2002 Feb; 12(1):86-91. PubMed ID: 11790560
[TBL] [Abstract][Full Text] [Related]
6. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
Atipairin A; Canyuk B; Ratanaphan A
Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein.
Xia Y; Pao GM; Chen HW; Verma IM; Hunter T
J Biol Chem; 2003 Feb; 278(7):5255-63. PubMed ID: 12431996
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
Eakin CM; Maccoss MJ; Finney GL; Klevit RE
Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5794-9. PubMed ID: 17392432
[TBL] [Abstract][Full Text] [Related]
9. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
Hashizume R; Fukuda M; Maeda I; Nishikawa H; Oyake D; Yabuki Y; Ogata H; Ohta T
J Biol Chem; 2001 May; 276(18):14537-40. PubMed ID: 11278247
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitination and proteasome-mediated degradation of BRCA1 and BARD1 during steroidogenesis in human ovarian granulosa cells.
Lu Y; Amleh A; Sun J; Jin X; McCullough SD; Baer R; Ren D; Li R; Hu Y
Mol Endocrinol; 2007 Mar; 21(3):651-63. PubMed ID: 17185394
[TBL] [Abstract][Full Text] [Related]
11. Control of biochemical reactions through supramolecular RING domain self-assembly.
Kentsis A; Gordon RE; Borden KL
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15404-9. PubMed ID: 12438698
[TBL] [Abstract][Full Text] [Related]
12. Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Atipairin A; Canyuk B; Ratanaphan A
J Biol Inorg Chem; 2011 Feb; 16(2):217-26. PubMed ID: 20967475
[TBL] [Abstract][Full Text] [Related]
13. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
Fabbro M; Schuechner S; Au WW; Henderson BR
Exp Cell Res; 2004 Aug; 298(2):661-73. PubMed ID: 15265711
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
Kiewhuo K; Priyadarsinee L; Sarma H; Sastry GN
J Biomol Struct Dyn; 2023; 41(22):12734-12752. PubMed ID: 36775657
[TBL] [Abstract][Full Text] [Related]
15. Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.
Nelson AC; Holt JT
Radiat Res; 2010 Jul; 174(1):1-13. PubMed ID: 20681793
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 as tumor suppressor: lord without its RING?
Elia AE; Elledge SJ
Breast Cancer Res; 2012 Apr; 14(2):306. PubMed ID: 22494569
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Morris JR; Pangon L; Boutell C; Katagiri T; Keep NH; Solomon E
Hum Mol Genet; 2006 Feb; 15(4):599-606. PubMed ID: 16403807
[TBL] [Abstract][Full Text] [Related]
18. Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.
Au WW; Henderson BR
Cell Signal; 2007 Sep; 19(9):1879-92. PubMed ID: 17531442
[TBL] [Abstract][Full Text] [Related]
19. Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Wu LC; Wang ZW; Tsan JT; Spillman MA; Phung A; Xu XL; Yang MC; Hwang LY; Bowcock AM; Baer R
Nat Genet; 1996 Dec; 14(4):430-40. PubMed ID: 8944023
[TBL] [Abstract][Full Text] [Related]
20. Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.
Starita LM; Young DL; Islam M; Kitzman JO; Gullingsrud J; Hause RJ; Fowler DM; Parvin JD; Shendure J; Fields S
Genetics; 2015 Jun; 200(2):413-22. PubMed ID: 25823446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
